


**EXAMINER'S AMENDMENT**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**




1. (Currently Amended) A compound of ~~Compounds of the~~ formula I







in which

- X denotes H, or F, Cl, Br, I, CN, OCN, SCN, COR<sup>2</sup>, COOR<sup>2</sup>, CONR<sup>2</sup>R<sup>3</sup>, imidazolyl, pyrazolyl, triazolyl or tetrazolyl,
- Y denotes -CHR<sup>2</sup>-CHR<sup>2</sup>- or -CR<sup>2</sup>=CR<sup>2</sup>-,
- Q denotes ~~O, OH, NH, NH<sup>2</sup>, NR<sup>2</sup>R<sup>3</sup>~~, C=O, CHOH, CHNH<sub>2</sub>, C=NH, CHOR<sup>2</sup> or CNR<sup>2</sup>R<sup>3</sup>,
- R<sup>1</sup> denotes branched or unbranched alkylcycloalkyl, alkaryl or alkheteroaryl, each of which is mono- or polysubstituted by X,
- R<sup>2</sup> denotes H or linear or branched alkyl or alkaryl,
- R<sup>3</sup> denotes H or linear or branched alkyl or alkaryl R<sup>2</sup>, and
- m and n, independently of one another, denote 1, 2 or 3,
- or a salt, racemate, enantiomer or diastereomer thereof or a mixture thereof and salts, solvates, racemates, enantiomers and diastereomers thereof and mixtures thereof in all ratios.

- <sup>6</sup>  
~~2.~~ (Currently Amended) A compound, which is of formula I1, I2, I3, I4, I5, I6 or I7 ~~Compounds of the formula I selected from a group consisting of the compounds I1 to I7:~~







17

or a salt thereof.

<sup>9</sup>  
~~2.~~ (Currently Amended) A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts and solvates thereof as medicaments.~~

<sup>10</sup>  
~~4.~~ (Currently Amended) A method for antagonizing ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts and solvates thereof as medicaments having a 5-HT<sub>2A</sub> receptor, comprising administering to a subject in need thereof an effective amount of a compound of claim 1~~ receptor-antagonistic action.

<sup>11</sup>  
~~5.~~ (Withdrawn and Currently Amended) A method for treating ~~Medicaments according to Claim 4 for the treatment of psychoses, schizophrenia, depression, a neurological disorder disorders, a memory disorder disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder disorders, such as bulimia, a panic attack attacks, anorexia nervosa, a sleeping disorder disorders, such as also sleep apnoea, or of premenstrual syndrome, or a method for the prophylaxis of or and for combating the consequences of cerebral infarction phenomena, such as strokes stroke or and cerebral ischaemia, and/or or a method for positively influencing~~ obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

<sup>12</sup>  
~~6.~~ (Currently Amended) A pharmaceutical composition, comprising a

compound of claim ~~2~~ and a pharmaceutically acceptable carrier ~~Pharmaceutical composition~~  
comprising at least one medicament according to Claim 5 and optionally excipients and/or  
adjuvants and optionally other active ingredients.

13

~~7.~~ (Withdrawn and Currently Amended) A method for antagonizing Use  
of compounds according to Claim 1 and/or of physiologically acceptable salts and solvates  
thereof for the preparation of a medicament having a 5-HT<sub>2A</sub> receptor, comprising  
administering to a subject in need thereof an effective amount of a compound of claim ~~2~~<sup>6</sup>  
~~receptor-antagonistic action.~~

14

~~8.~~ (Withdrawn and Currently Amended) A method for treating Use  
according to Claim 7 for the preparation of a medicament for the treatment of psychoses,  
schizophrenia, depression, ~~a neurological disorder disorders, a memory disorder disorders,~~  
Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease,  
~~an eating disorder disorders, such as bulimia, a panic attack attacks, anorexia nervosa, a~~  
~~sleeping disorder disorders, such as also sleep apnoea, or of premenstrual syndrome, or a~~  
~~method for the prophylaxis of or and for combating the consequences of cerebral infarction~~  
~~phenomena, such as strokes stroke or and cerebral ischaemia, and/or or a method for~~  
~~positively influencing~~<sup>OR</sup> obsessive-compulsive disorder (OCD), comprising administering to a  
subject in need thereof an effective amount of a compound of claim ~~2~~.

15

~~9.~~ (New) A method for treating psychoses, comprising administering to a  
subject in need thereof an effective amount of a compound of claim 1.

16

~~10.~~ (New) A method for treating psychoses, comprising administering to a  
subject in need thereof an effective amount of a compound of claim ~~2~~<sup>6</sup>.

17




~~11.~~ (New) A method for treating Parkinson's disease, comprising  
administering to a subject in need thereof an effective amount of a compound of claim 1.




18

~~12.~~ (New) A method for treating Parkinson's disease, comprising <sup>6</sup>  
administering to a subject in need thereof an effective amount of a compound of claim ~~2~~.


8  
13. (New)

A compound, which is one of the following compounds





or




wherein

R	R'	R''
F	OH	F
F	NH <sub>2</sub>	F
OCN	OH	F
OCN	N(CH <sub>3</sub> ) <sub>2</sub>	F
F	OH	CN
F	NH <sub>2</sub>	CN
OCN	OH	CN
OCN	N(CH <sub>3</sub> ) <sub>2</sub>	CN
COCF <sub>3</sub>	OH	CN
COCF <sub>3</sub>	NH <sub>2</sub>	CN or
COCF <sub>3</sub>	N(CH <sub>3</sub> ) <sub>2</sub>	CN

or





wherein

R	R'	R''
F	OH	F
F	NH <sub>2</sub>	F
OCN	OH	F
OCN	N(CH <sub>3</sub> ) <sub>2</sub>	F
F	OH	CN
F	NH <sub>2</sub>	CN
OCN	OH	CN
OCN	N(CH <sub>3</sub> ) <sub>2</sub>	CN
COCF <sub>3</sub>	OH	CN
COCF <sub>3</sub>	NH <sub>2</sub>	CN or
COCF <sub>3</sub>	N(CH <sub>3</sub> ) <sub>2</sub>	CN

or a salt thereof.

<sup>19</sup>  
~~14.~~ (New) A method for treating psychoses, comprising administering to a subject in need thereof an effective amount of a compound of claim ~~13~~<sup>8</sup>.

<sup>20</sup>  
~~15.~~ (New) A method for treating Parkinson's disease, comprising administering to a subject in need thereof an effective amount of a compound of claim ~~13~~<sup>8</sup>.

<sup>2</sup>  
~~16.~~ (New) A compound according to claim 1, wherein  
X denotes H, F or CN,

Y denotes  $-\text{CHR}^2-\text{CHR}^2-$  or  $-\text{CR}^2=\text{CR}^2-$ ,  
 Q denotes  $\text{C}=\text{O}$ ,  $\text{CHOH}$ , or  $\text{CNR}^2\text{R}^3$ ,  
 $\text{R}^1$  denotes unbranched alkaryl, which is monosubstituted by X,  
 $\text{R}^2$  denotes H or linear alkyl, and  
 $\text{R}^3$  denotes H or linear alkyl.

<sup>3</sup>  
~~17.~~ (New) A compound according to claim 1, wherein

X denotes H or F,  
 Y denotes  $-\text{CHR}^2-\text{CHR}^2-$  or  $-\text{CR}^2=\text{CR}^2-$ ,  
 Q denotes  $\text{C}=\text{O}$ ,  $\text{CHOH}$ , or  $\text{CNR}^2\text{R}^3$ ,  
 $\text{R}^1$  denotes unbranched alkaryl, which is monosubstituted by X,  
 $\text{R}^2$  denotes H or linear alkyl, and  
 $\text{R}^3$  denotes H or linear alkyl.

<sup>4</sup>  
~~18.~~ (New) A compound according to claim 1, wherein

X denotes H, F or CN,  
 Y denotes  $-\text{CR}^2=\text{CR}^2-$ ,  
 Q denotes  $\text{CHOH}$ ,  
 $\text{R}^1$  denotes unbranched alkaryl, which is monosubstituted by X, wherein aryl is phenyl, and  
 $\text{R}^2$  denotes H.

<sup>5</sup>  
~~19.~~ (New) A compound according to claim 1, wherein

X denotes H or F,  
 Y denotes  $-\text{CR}^2=\text{CR}^2-$ ,  
 Q denotes  $\text{CHOH}$ ,  
 $\text{R}^1$  denotes unbranched alkaryl, which is monosubstituted by X, wherein aryl is phenyl, and  
 $\text{R}^2$  denotes H.

<sup>7</sup> <sup>6</sup>  
~~20.~~ (New) A compound according to claim ~~2~~, which is of formula I7 or a pharmaceutically acceptable salt thereof.